Mini-Tumor biobank could revolutionize cancer drug testing
NCT ID NCT05384184
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study aimed to create a biobank of 'organoids'—tiny, 3D mini-tumors grown from liver cancer tissue. Researchers collected samples from 48 patients with colorectal cancer that spread to the liver or with primary liver cancer. The goal was to see if they could reliably grow and store these personalized organoids for future drug testing, potentially leading to more tailored cancer treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this biobank could provide a powerful tool for testing cancer drugs on personalized mini-tumors, helping doctors choose the right treatment for each patient.
- What could go wrong
- This is a feasibility study with only 48 participants, focused on building the biobank, not testing treatments. The organoids may not fully predict real patient responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ap-HM hopital nord
Marseille, 13915, France